Kisunla Approved by FDA, 2nd Drug to Actually Slow Alzheimer’s [AlzWeek.com] [Video]

The U.S. Food and Drug Administration (FDA) has approved Kisunla™ (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly and Company. (Article continued below video..)

Kisunla is intended for adults with early symptomatic Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI) and individuals in the mild dementia stage of AD, with confirmed amyloid pathology.

Notably, Kisunla is the first and only amyloid plaque-targeting therapy that allows for stopping therapy when amyloid plaques are removed, potentially reducing treatment costs and minimizing infusions.

35% Slowing, 39% Risk Reduction

In clinical trials, Kisunla significantly slowed cognitive and functional decline by up to 35% compared to placebo at 18 months. It also reduced the risk of progressing to the next clinical stage of the disease by up to 39%. 

The treatment involves once-monthly infusions and has shown promising results in people at different stages of the disease^1,2.

Meaningful Results

“Kisunla demonstrated very meaningful results for …